Gregory Philip D Form 4 March 07, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005 Estimated average burden hours per response... 0.5

OMB APPROVAL

3235-0287

OMB

Number:

Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Gregory Philip D

2. Issuer Name and Ticker or Trading Symbol bluebird bio, Inc. [BLUE]

5. Relationship of Reporting Person(s) to Issuer

(Last)

(First) (Middle)

(Check all applicable)

C/O BLUEBIRD BIO, INC., 60

3. Date of Earliest Transaction

(Month/Day/Year) 03/05/2019

Director 10% Owner _X__ Officer (give title Other (specify

(Street)

BINNEY STREET

4. If Amendment, Date Original

Chief Scientific Officer 6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

below)

CAMBRIDGE, MA 02142

(City)	(State)	(Zip) Tab	le I - Non-	Derivativ	e Seci	ırities Acquir	ed, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Transaction Disposed Code (Instr. 3, 4 a (Instr. 8)			(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. 7. Nature of Ownership Indirect Form: Beneficial Direct (D) Ownership or Indirect (Instr. 4) (I) (Instr. 4)	
Common Stock	03/05/2019		M	600	(D)	\$ 50.51	33,692	D	
Common Stock	03/05/2019		M	700	A	\$ 75.6	34,392	D	
Common Stock	03/05/2019		S(1)	600	D	\$ 146.015 (2)	33,792	D	
Common Stock	03/05/2019		S <u>(1)</u>	300	D	\$ 147.3767 (3)	33,492	D	
Common Stock	03/05/2019		S <u>(1)</u>	300	D	\$ 148.5783	33,192	D	

Edgar Filing: Gregory Philip D - Form 4

(4) \$ Common 03/05/2019 $S^{(1)}$ 600 D 149.1392 32,592 D Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 50.51	03/05/2019		M	600	<u>(6)</u>	03/01/2026	Common Stock	600	\$
Stock Option (right to buy)	\$ 75.6	03/05/2019		M	700	<u>(7)</u>	02/01/2027	Common Stock	700	\$

Reporting Owners

Relationships Reporting Owner Name / Address Director 10% Owner Officer Other

Gregory Philip D C/O BLUEBIRD BIO, INC. **60 BINNEY STREET** CAMBRIDGE, MA 02142

Chief Scientific Officer

2 Reporting Owners

Signatures

/s/ Jason F. Cole, Attorney-in-Fact

03/07/2019

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
- The range in prices for the transaction reported on this line was \$146.00 to \$146.06. The average weighted price was \$146.015. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was \$147.15 to \$147.54. The average weighted price was \$147.3767. The (3) reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was \$148.555 to \$148.61. The average weighted price was \$148.5783. The (4) reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was \$149.01 to \$149.32. The average weighted price was \$149.1392. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (6) This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter
- (7) This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2018 and in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3